Our results showed that ARNTL2-high PC-PDX-1 and PC-PDX-2 were more sensitive to erlotinib treatment and showed a substantial reduction in vivo tumor growth (Fig. 7B-D and Fig. 7F-H). The gene discussed is BMAL2; the disease is neoplasm.